No IGF-1 elevation side effect
BPC-157 and TB-500 Blend Peptide Gel is sold for laboratory research use only
Trial SURMOUNT-5 (NEJM 2025) Population 751 adults, obesity, no diabetes
Re-check the concentration and draw volume against the math above an under-mixed or mis-drawn dose is the most common stall. Verify the four-week hold is complete before expecting the next steps effect
[DOI] [PMC free article] [PubMed] [Google Scholar] 16.Rudolphi B, Zapp B, Kraus NA, Ehebauer F, Kraus B, Kraus D
Clinical Indications Acute and chronic musculoskeletal injuries (e.g., tendonitis, sprains, muscle strains) Post-surgical recovery protocols Chronic joint or soft tissue inflammation Gastrointestinal injuries or ulcers (BPC-157) Final Thoughts Peptide therapies like Ipamorelin/CJC-1295 and the Wolverine Stack (BPC-157/TB-500) represent a new frontier in regenerative and performance medicine